TriSalus Life Sciences (TLSI) to Release Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to be issuing its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect TriSalus Life Sciences to post earnings of ($0.13) per share and revenue of $13.20 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

TriSalus Life Sciences Stock Down 5.9%

Shares of TLSI stock opened at $5.06 on Friday. The stock has a market cap of $252.80 million, a P/E ratio of -2.50 and a beta of 0.42. TriSalus Life Sciences has a fifty-two week low of $3.42 and a fifty-two week high of $7.95. The business has a fifty day simple moving average of $5.59 and a 200-day simple moving average of $5.33.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Canaccord Genuity Group increased their price target on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Finally, Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Hold” and a consensus target price of $12.00.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors have recently added to or reduced their stakes in TLSI. JPMorgan Chase & Co. boosted its stake in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in TriSalus Life Sciences in the 2nd quarter worth $47,000. Invesco Ltd. purchased a new position in TriSalus Life Sciences in the 4th quarter valued at about $72,000. Abel Hall LLC acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at about $73,000. Finally, Man Group plc purchased a new stake in shares of TriSalus Life Sciences during the fourth quarter worth about $102,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.